Advertisement Covers CROI 2017


Long-Acting HIV Treatment: 5 Myths and Realities

March 17, 2017


Charles W. Flexner, M.D.

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by?

As research progresses on long-acting antiretroviral therapy (LA-ART) for HIV -- also sometimes referred to as extended-release (ER) antiretroviral therapy -- experts disagree about the impact it will have on clinical care. There is both optimism and pessimism regarding LA-ART, and sometimes they come from the same person, as was the case at CROI 2017 in Seattle, Washington.

At this major gathering of HIV researchers and clinical experts, Charles W. Flexner, M.D., a professor of medicine at Johns Hopkins University, gave a presentation in which he refuted what he regarded as five common LA-ART myths -- while retaining his own healthy dose of skepticism about LA-ART's ultimate value for people living with HIV.

Image credit: Myles Helfand.

Related Stories

Really Rapid Review -- CROI 2017, Seattle
A Review of Long-Acting HIV Treatment and Prevention
Introduction to Long-Acting Injectables

This article was provided by It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.